Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'

Find Full text
Thumbnail
Fulltext:
190897.pdf
Embargo:
until further notice
Size:
283.0Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2018
Author(s)
Schoffski, P.
Wozniak, Agnieszka
Kasper, B.
Aamdal, S.
Leahy, M.G.
Rutkowski, P.
Graaf, W.T.A. van der
Collette, S.
Stacchiotti, S.
Source
Annals of Oncology, 29, 3, (2018), pp. 758-765
ISSN
DOI
Publication type
Article / Letter to editor
Please use this identifier to cite or link to this item: https://hdl.handle.net/2066/190897   https://hdl.handle.net/2066/190897
Display more details

Upload full text

Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.